Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKwan, E M-
dc.contributor.authorThangasamy, I A-
dc.contributor.authorTeh, J-
dc.contributor.authorAlghazo, O-
dc.contributor.authorSathianathen, N J-
dc.contributor.authorLawrentschuk, N-
dc.contributor.authorAzad, A A-
dc.identifier.citationWorld Journal of Urology 2021; 39(2): 339-348en
dc.description.abstractThe last decade has seen a remarkable shift in the treatment landscape of advanced prostate cancer, none more so than in the management of metastatic castration-naïve disease. This narrative review will examine existing and emerging evidence supporting systemic therapy use for metastatic castration-naïve prostate cancer (mCNPC) and provide guidance on the selection of these agents with respect to optimising patient outcomes. The addition of either docetaxel (chemohormonal approach) or an AR pathway inhibitor (abiraterone, enzalutamide or apalutamide) is a reasonable standard of care option for men commencing long-term ADT for mCNPC. While the issue of disease volume as a predictive biomarker for docetaxel benefit has previously been debated, recent data support consideration of upfront docetaxel in all patients, regardless of metastatic burden. Decisions regarding systemic treatment for men with mCNPC should be based on comprehensive consideration of disease, patient and logistical factors. Multiple novel therapeutics for mCNPC are currently under active investigation. The introduction of potent systemic therapy earlier in the mCNPC disease course has resulted in dramatic improvements in clinical outcomes for patients. As the management of mCNPC continues to evolve, the future remains promising, with the expectation of ongoing improvements to patient outcomes and quality of life.en
dc.subjectAndrogen receptor pathway inhibitorsen
dc.subjectMetastatic prostate canceren
dc.titleNavigating systemic therapy for metastatic castration-naïve prostate cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleWorld Journal of Urologyen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Monash Health, Melbourne, Australiaen
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationFaculty of Medicine, University of Queensland, Brisbane, Australiaen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Oct 3, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.